Literature DB >> 28920946

Potential niche indications for blinatumomab as a bridge to hematopoietic cell transplantation.

Yi Zeng1,2,3, Emmanuel Katsanis1,2,3,4,5,6.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28920946     DOI： 10.1038/bmt.2017.186

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  2 in total

1.  Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia.

Authors:  Amy K Keating; Nathan Gossai; Christine L Phillips; Kelly Maloney; Kristen Campbell; Andrew Doan; Deepa Bhojwani; Michael J Burke; Michael R Verneris
Journal:  Blood Adv       Date:  2019-07-09

Review 2.  Bispecific Antibodies and Other Non-CAR Targeted Therapies and HSCT: Decreased Toxicity for Better Transplant Outcome in Paediatric ALL?

Authors:  Krisztián Miklós Kállay; Mattia Algeri; Jochen Buechner; Aviva C Krauss
Journal:  Front Pediatr       Date:  2022-02-02       Impact factor: 3.418
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.